NEW YORK, Sept. 26, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/abbv.
The investigation concerns whether AbbVie and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On September 18, 2018, media outlets reported that California's insurance regulator had sued AbbVie, alleging that the Company provided unlawful kickbacks to healthcare providers in order to induce them to prescribe AbbVie's rheumatoid arthritis drug Humira. Following this news, AbbVie's stock price fell $2.76, or 2.89%, to close at $92.61 on September 18, 2018.
If you are aware of any facts relating to this investigation, or purchased AbbVie shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/abbv. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
SOURCE Bronstein, Gewirtz & Grossman, LLC